Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25136611 | 0.76 | MAOA (0.44) | MAOAMAOBKDM1AOPRM1OPRL1 | |
| SCHEMBL21937925 | 0.75 | CYP2D6 (0.37) | OPRM1OPRL1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL21038542 | 0.73 | OPRM1 (0.40) | MAOAMAOBKDM1AOPRM1OPRL1 | |
| SCHEMBL24393952 | 0.72 | OPRL1 (0.44) | MAOAMAOBKDM1AOPRM1OPRL1 | |
| SCHEMBL18358295 | 0.72 | MAOA (0.48) | MAOAMAOBKDM1AOPRM1OPRL1 | |
| SCHEMBL5698924 | 0.69 | MAOA (0.46) | MAOAMAOBKDM1AOPRM1OPRL1 | |
| SCHEMBL5698923 | 0.69 | MAOA (0.46) | MAOAMAOBKDM1AOPRM1OPRL1 | |
| SCHEMBL21134568 | 0.66 | SLC6A3 (0.46) | MAOAMAOBKDM1AOPRM1OPRL1 | |
| SCHEMBL9604744 | 0.65 | SLC6A3 (0.35) | OPRM1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL13838853 | 0.65 | OPRL1 (0.52) | MAOAMAOBKDM1AOPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | MAOA 1402/4885MAOB 1380/4885KDM1A 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.